Metropolis Healthcare Ltd

Dapic Metropolis Healthcare (formerly known as Metropolis Histoxpert Digital Services), a wholly owned subsidiary of Metropolis Healthcare, has completed the acquisition of entire business of Dr. Ahujas' Pathology & Imaging Centre (DAPIC - a partnership firm), Dr. Alok Ahuja and Dr. Alka Ahuja (collectively referred to as 'acquired business') as a going-concern, effective 23 May 2025, in accordance with the terms agreed under the Business Transfer Agreement. Following the completion of the acquisition, the operations of the acquired business are now being carried out under Dapic Metropolis Healthcare effective 23 May 2025. Powered by Capital Market - Live

Despite the dip in profit, revenue from operations rose 4.31% year-on-year (YoY) to Rs 345.29 crore for the quarter ended 31 March 2025. Profit before tax fell 28.67% to Rs 36.04 crore in Q4 FY25, compared to Rs 50.53 crore recorded in the same quarter last year. EBITDA increased by 5% YoY to Rs 84 crore, compared to Rs 80 crore in Q4 FY24. However, the EBITDA margin declined to 24.3% in Q4 FY25 from 25.5% in the same quarter last year. The company continued to achieve growth in both patient and test volumes, while strategically reducing its exposure to the low-margin institutional business. Strong B2C growth was driven by infrastructure expansion and a greater focus on wellness services. The B2B segment posted double-digit growth, supported by enhancements in service quality and partner engagement. The TruHealth and Specialty segments emerged as the fastest-growing areas, aligning with the company's strategic focus. TruHealth revenues rose 20% YoY and contributed 19% to total revenues in Q4 FY25. B2C revenue for the quarter grew 14% YoY, with Maharashtra registering a notable 19% YoY increase in this segment. The specialty diagnostics segment posted 11% YoY growth. For FY25, patient volume increased by 6% YoY, while test volume rose by 7%. Revenue per patient also saw robust 6% YoY growth, supported by scientific upselling and micro-market pricing strategies. B2C revenues grew 17% YoY in FY25 and 14% YoY in Q4 FY25, reflecting the company's investments in consumer experience and network expansion. B2B revenue increased 12% YoY in FY25 and 10% YoY in Q4 FY25, driven by enhanced service quality and partner engagement. TruHealth revenues grew 24% YoY in FY25, with a strong Q4 contribution of 19% to total revenue. The specialty diagnostics segment maintained momentum with 13% YoY growth in FY25. Revenue growth from Tier III cities stood at 18% in FY25. The company expanded its reach to over 750 towns, adding 29 new labs and 400 centers during the year, thereby strengthening last-mile access. On a full-year basis, the company's consolidated net profit rose 13.41% to Rs 144.97 crore, on a 10.22% increase in revenue to Rs 1,331.20 crore in FY25 over FY24. Ameera Shah, executive chairperson & whole-time director, Metropolis Healthcare, said, 'Over the past four years, Metropolis has built a resilient, future-ready organization through strategic investments in laboratories, network expansion, brand, technology, and talent. Despite a challenging environment, we have strengthened our scientific leadership, enhanced customer engagement, and driving operational excellence. We are confident that our recent acquisitions ' Core Diagnostics, Scientific Pathology, and Dr. Ahuja's Pathology & Imaging Centre ' will generate strong returns and fuel the next phase of growth. These acquisitions reinforce our leadership in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India. With a robust foundation, a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value. Surendran Chemmenkotil, chief executive officer, Metropolis Healthcare, said, 'FY25 has been a pivotal year in our journey toward becoming a more consumer-centric and digitally enabled diagnostics brand. Our growth was fuelled by rising demand for preventive and specialized testing, enabled by focused execution, stronger clinician engagement, and meaningful innovation. We introduced industry-first cancer screening panels and tools, along with AI-powered diagnostics to enhance accuracy and enable early detection. Our proprietary engine, MetAdvisor, uses historical data to deliver personalized, science-led test recommendations'boosting TruHealth performance. As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care. With science at the heart of our efforts, we aim to make quality diagnostics more accessible, reliable, and impactful for the communities we serve.' Meanwhile, the company's board has approved the re-appointment of Ameera Shah as chairperson and whole-time director of the company for a term of five consecutive years, commencing from 18 March 2026 to 17 March 2031 (both days inclusive), subject to the approval of the shareholders. Further, the board has also approved the appointment of Surendran Chemmenkotil, currently serving as chief executive officer, as an additional director designated as managing director of the company for a term of three consecutive years, commencing from 01 June 2025 to 31 May 2028, subject to shareholder approval. Furthermore, Surendran Chemmenkotil will step down from his position as chief executive officer with effect from the close of business hours on 31 May 2025. Metropolis Healthcare is a diagnostics company with a presence in 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,400 patient service centers, and over 10,000 touchpoints. It offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. Powered by Capital Market - Live

Net profit of Metropolis Healthcare declined 19.97% to Rs 29.14 crore in the quarter ended March 2025 as against Rs 36.41 crore during the previous quarter ended March 2024. Sales rose 4.32% to Rs 345.29 crore in the quarter ended March 2025 as against Rs 331.00 crore during the previous quarter ended March 2024. For the full year,net profit rose 13.42% to Rs 144.97 crore in the year ended March 2025 as against Rs 127.82 crore during the previous year ended March 2024. Sales rose 10.23% to Rs 1331.20 crore in the year ended March 2025 as against Rs 1207.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales345.29331.00 4 1331.201207.71 10 OPM %18.0424.16 -22.7623.40 - PBDT64.6776.95 -16 299.53269.16 11 PBT36.0450.53 -29 190.85174.69 9 NP29.1436.41 -20 144.97127.82 13 Powered by Capital Market - Live

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live

Metropolis Histoxpert Digital Services is a wholly owned subsidiary of Metropolis Healthcare. Dr. Ahujas' Pathology and Imaging Centre (DAPIC) operates two laboratories accredited by National Accreditation Board for Testing and Calibration Laboratories (NABL) and National Accreditation Board for Hospitals and Healthcare Providers (NABH) 11 patient service centres, and nine hospital-based centres. DAPIC offers a comprehensive range of pathology and soft radiology services, including ultrasound, ECG, and X-ray. In FY 2024-25, DAPIC recorded an estimated annual revenue of INR 11.5 crore (unaudited*), with pathology services contributing 73% and radiology services 27%. With 80 percent of its revenue coming from walk-in patients, the chain has built a strong B2C presence, making it a valuable addition to Metropolis' growing network in North India,' the company said in a statement. Under the agreement, Metropolis Histoxpert Digital Services will acquire 100% ownership of DAPIC in an all-cash deal valued at Rs 35.01 crore. To ensure a seamless transition, Dr. Alok Ahuja and Dr. Alka Ahuja will continue their association with the business post-acquisition. Ameera Shah, promoter and executive chairperson, Metropolis Healthcare, said: Dr. Ahujas' Pathology & Imaging Centre has established a strong reputation for high-quality B2C services, scientific excellence, and patient trust, making it an ideal addition to Metropolis' growth strategy. Together with the acquisition of Core Diagnostics, a leader in oncology testing, Scientific Pathology, the dominant chain in Agra, and now DAPIC, the leading diagnostic chain in Dehradun, we are further strengthening our 'String of Pearls' strategy'aimed at building a robust and regionally diverse diagnostic network across North India. These strategic moves have expanded the North India contribution to our overall revenues from 8% to an estimated 14'15%. Building on this momentum, we aim to accelerate our expansion across Uttar Pradesh and Uttarakhand'two high-growth markets with significant potential.' In an exchange filing made on Saturday, Metropolis Healthcare announced its operational updates for the quarter ended on 31 March 2025. The company's consolidated revenue in Q4 FY25 grew by approx. 10% on a year-on-year (Y-o-Y) basis. Revenue growth was driven by patient volume growth, test volume growth and change in product mix coupled with realization benefits. The B2C revenues grew at approximately 14% on a Y-o-Y basis on account of consumer experience and expansion of service network. The operational EBITDA for the current quarter has grown marginally lower due to higher material costs and reduced revenue growth. Reported EBIDTA is lower due to one-time costs including acquisition costs for Core Diagnostics & Scientific Pathology and lower margin from Core Diagnostics. The company is debt free & has cash reserves of approximately Rs 112 crore, post paying towards acquisition amounting to Rs 130 crore as on 31 March 2025. Metropolis Healthcare is India's second largest diagnostic chain. The company's extensive footprint spans 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,300 service centres, and over 10,000 touchpoints. The scrip declined 3.04% to currently trade at Rs 1503.05 on the BSE. Powered by Capital Market - Live

Metropolis Healthcare announced that its wholly owned subsidiary, Metropolis Histoxpert Digital Services, has entered into a business transfer agreement to acquire Dehradun's leading diagnostic chain - Dr. Ahujas' Pathology and Imaging Centre (DAPIC). Under the agreement, Metropolis' wholly owned subsidiary Metropolis Histoxpert Digital Services, will acquire 100% ownership of DAPIC in an all-cash deal valued at INR 35.01 crores. To ensure a seamless transition, Dr. Alok Ahuja and Dr. Alka Ahuja will continue their association with the business post acquisition. Powered by Capital Market - Live

Revenue from operations grew 10.9% YoY to Rs 322.77 crore in the quarter ended 31 December 2024. Profit before tax jumped 14.9% to Rs 42.34 crore in Q3 FY25, compared to Rs 36.85 crore recorded in the same quarter last year. EBITDA stood at Rs 72 crore, registering the growth of 9.4% as compared with Rs 66 crore posted in the corresponding quarter last year. The EBITDA margin slightly decreased to 22.20% in Q3 FY25, down from 22.50% in Q3 FY24. The company reported strong B2C revenue growth of 15% year-over-year (YoY) in Q3FY25. Patient volume increased by 5%, while revenue per patient (RPP) saw a robust 10% growth, driven by enhanced upselling and value delivery. Additionally, B2B revenue grew by 10% YoY in Q3FY25, marking consistent double-digit growth for the third consecutive quarter. TruHealth revenue grew by 25% YoY, with its contribution rising from 14% in Q3 FY24 to 17% in Q3 FY25. The company's specialty revenue increased by 13% YoY, driven by a focus on specialized, non-seasonal tests. On nine-month basis, the company's consolidated net profit jumped 26.7% to Rs 115.83 crore in 9M FY25, compared to Rs 91.41 crore in 9M FY24. Revenue from operations rose 12.5% YoY to Rs 985.91 crore in 9M FY25. Ameera Shah, executive chairperson & whole-time director, Metropolis Healthcare, said, 'The diagnostics industry is undergoing a paradigm shift towards personalized medicine, genomics-driven testing, and preventive healthcare, fueled by advancements in molecular diagnostics, AI, and nextgeneration sequencing. At Metropolis, we remain at the forefront of this transformation, leveraging deep scientific expertise and consumer insights to drive innovation and expand access to cutting-edge diagnostics. Our strategic acquisition of Core Diagnostics is a pivotal step in this direction, strengthening our oncology and molecular diagnostics portfolio and reinforcing our commitment to becoming India's leading cancer testing provider. As part of our long-term strategy, we are expanding our presence in North India through a'string of pearls' approach, focusing on acquiring high-performing B2C businesses that are leaders in their cities, with strong EBITDA, ROCE, and cash flows. This strategy will enhance our capabilities and deepen our footprint in the region, driving long-term value creation and solidifying Metropolis' leadership in the evolving diagnostics landscape. Surendran Chemmenkotil, CEO, Metropolis Healthcare, said, 'We have achieved double-digit growth for the third consecutive quarter, despite a traditionally challenging Q3 with lower illness-driven demand. This success stems from our focus on key segments, TruHealth and specialty, and our efforts to drive regional growth through targeted micro-marketing strategies and deeper market penetration. Through TruHealth' packages, we have been able to enhance the customer experience by integrating home-based ECG services, vital checks, and consultations. Additionally, the introduction of AI-powered MetAdvisor recommendation engine further personalises care by analyzing historical data and test combinations. With strong partnerships and an expanding network, we remain committed to addressing regional healthcare needs and driving sustainable growth. Our continued investments in technology and service excellence will deliver lasting value to customers and stakeholders. Meanwhile, the company's board has approved the appointment of Sameer Patel as chief financial officer and key managerial personnel of the company effective from 10 February 2025. This appointment will relieve Aditya Shinde from the additional role of Interim chief financial officer and key managerial personnel of the company effective from the close business hours of 09 February 2025. Aditya Shinde will continue to serve as Finance Controller. Metropolis Healthcare is a diagnostics company, with presence in 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,400 patient service centers, and over 10,000 touchpoints. It offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. Powered by Capital Market - Live

Net profit of Metropolis Healthcare rose 15.46% to Rs 31.36 crore in the quarter ended December 2024 as against Rs 27.16 crore during the previous quarter ended December 2023. Sales rose 10.87% to Rs 322.77 crore in the quarter ended December 2024 as against Rs 291.12 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales322.77291.12 11 OPM %22.3122.27 - PBDT70.0361.85 13 PBT42.3436.85 15 NP31.3627.16 15 Powered by Capital Market - Live

Metropolis Healthcare has allotted Sameer Patel as Chief Financial Officer and Key Managerial Personnel of the Company effective from 10 February 2025. This appointment will relieve Aditya Shinde from the additional role of Interim Chief Financial Officer and Key Managerial Personnel of the Company effective from the close business hours of 09 February 2025. Aditya Shinde will continue to serve as Finance Controller.Powered by Capital Market - Live

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live